JP7352284B2 - ＬＳＤ－１インヒビターとしてのピロロ〔２，３－ｃ〕ピリジン及び関連類似体 - Google Patents

ＬＳＤ－１インヒビターとしてのピロロ〔２，３－ｃ〕ピリジン及び関連類似体 Download PDF

Info

Publication number
JP7352284B2
JP7352284B2 JP2019563164A JP2019563164A JP7352284B2 JP 7352284 B2 JP7352284 B2 JP 7352284B2 JP 2019563164 A JP2019563164 A JP 2019563164A JP 2019563164 A JP2019563164 A JP 2019563164A JP 7352284 B2 JP7352284 B2 JP 7352284B2
Authority
JP
Japan
Prior art keywords
group
alkyl
optionally substituted
cancer
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019563164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519667A5 (cg-RX-API-DMAC7.html
JP2020519667A (ja
Inventor
ワン シャオメン
チャン トンヨウ
チェン ツァンホイ
チェン チュオ
リウ リウ
ホアン リーユエ
ヤン チャオ－イエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan (System)
Original Assignee
University of Michigan (System)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan (System) filed Critical University of Michigan (System)
Publication of JP2020519667A publication Critical patent/JP2020519667A/ja
Publication of JP2020519667A5 publication Critical patent/JP2020519667A5/ja
Application granted granted Critical
Publication of JP7352284B2 publication Critical patent/JP7352284B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2019563164A 2017-05-15 2018-05-15 ＬＳＤ－１インヒビターとしてのピロロ〔２，３－ｃ〕ピリジン及び関連類似体 Active JP7352284B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762506349P 2017-05-15 2017-05-15
US62/506,349 2017-05-15
PCT/US2018/032619 WO2018213211A1 (en) 2017-05-15 2018-05-15 Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors

Publications (3)

Publication Number Publication Date
JP2020519667A JP2020519667A (ja) 2020-07-02
JP2020519667A5 JP2020519667A5 (cg-RX-API-DMAC7.html) 2021-07-26
JP7352284B2 true JP7352284B2 (ja) 2023-09-28

Family

ID=62685119

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019563164A Active JP7352284B2 (ja) 2017-05-15 2018-05-15 ＬＳＤ－１インヒビターとしてのピロロ〔２，３－ｃ〕ピリジン及び関連類似体

Country Status (6)

Country Link
US (1) US11168082B2 (cg-RX-API-DMAC7.html)
EP (1) EP3628044B1 (cg-RX-API-DMAC7.html)
JP (1) JP7352284B2 (cg-RX-API-DMAC7.html)
CN (1) CN110914265B (cg-RX-API-DMAC7.html)
AU (2) AU2018269947B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018213211A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112119080B (zh) * 2018-05-15 2023-07-11 密歇根大学董事会 作为lsd-1抑制剂的咪唑并[4,5-c]吡啶化合物
SI3941466T1 (sl) 2019-03-20 2026-04-30 Oryzon Genomics, S.A. Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje
HRP20251471T1 (hr) 2019-03-20 2026-01-02 Oryzon Genomics, S.A. Postupci liječenja poremećaja hiperaktivnosti s deficitom pažnje korištenjem inhibitora kdm1a kao što je spoj vafidemstat
US20220227763A1 (en) 2019-05-29 2022-07-21 Syngenta Crop Protection Ag Microbiocidal derivatives
CN112451671B (zh) * 2020-12-02 2021-11-02 武汉大学 KDM1A在抑制RNA病毒刺激下干扰素IFNβ表达中的应用
CA3231846A1 (en) 2021-04-08 2022-10-13 Tamara Maes Combinations of lsd1 inhibitors for treating myeloid cancers
CN116102533A (zh) * 2021-11-11 2023-05-12 中国科学院上海药物研究所 一种芳杂环类化合物及其应用
JP2025503099A (ja) * 2022-01-25 2025-01-30 成都苑▲東▼生物制▲薬▼股▲ふん▼有限公司 ピリジン系誘導体、その製造方法及び使用
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
US20250275969A1 (en) 2022-05-09 2025-09-04 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
AU2023327925A1 (en) * 2022-08-22 2025-02-20 Redx Pharma Limited Pyrido-pyrazoles as inhibitors of ddr's for the treatment of fibrotic disorders and cancer
US20260151399A1 (en) 2022-11-24 2026-06-04 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
WO2024208187A1 (zh) * 2023-04-03 2024-10-10 上海复星医药（集团）股份有限公司 氮杂芳基化合物及其作为lsd1抑制剂的用途
EP4784570A1 (en) * 2023-09-28 2026-08-05 The Regents of The University of Michigan Oxygenated heterocyclic lsd-1 inhibitors and related methods of use

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001697A1 (en) 1998-07-02 2000-01-13 Du Pont Pharmaceuticals Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
JP2002507996A (ja) 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
JP2008540664A (ja) 2005-05-16 2008-11-20 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としてのピロロピリジン誘導体
JP2009523812A (ja) 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
JP2010508363A (ja) 2006-11-01 2010-03-18 バーテックス ファーマシューティカルズ インコーポレイテッド ヤヌスキナーゼの阻害剤として有用な三環系ヘテロアリール化合物
JP2010528026A (ja) 2007-05-18 2010-08-19 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのキノリン誘導体
JP2010537998A (ja) 2007-08-27 2010-12-09 ワイス・エルエルシー イミダゾピリジン類似体、およびＷｎｔ−βカテニン細胞メッセージ伝達系のアゴニストとしてのその使用
JP2013529196A (ja) 2010-05-14 2013-07-18 メディカル リサーチ カウンシル テクノロジー キナーゼｌｒｒｋ２の阻害剤としてのピラゾロピリジン
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
JP2017502940A (ja) 2013-12-11 2017-01-26 セルジーン クオンティセル リサーチ，インク． リジン特異的デメチラーゼ−１の阻害剤
JP2020506197A (ja) 2017-02-07 2020-02-27 デウン ファーマシューティカル カンパニー リミテッド 新規なヘテロ環化合物、その製造方法およびこれを含む薬学的組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
EP2295550A3 (en) * 2001-04-30 2011-12-14 Vertex Pharmaceuticals Incorporated Crystal structures of GSK-3beta protein and protein complexes and their use
US20100130496A1 (en) * 2007-04-12 2010-05-27 F. Hoffmann-La Roche Ag Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
WO2008138184A1 (fr) * 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
JP5744021B2 (ja) * 2010-06-30 2015-07-01 富士フイルム株式会社 新規なニコチンアミド誘導体またはその塩
KR20150024669A (ko) * 2013-08-27 2015-03-09 제일모직주식회사 화합물, 이를 포함하는 유기발광소자 및 상기 유기발광소자를 포함하는 표시장치
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
WO2015123424A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EA201792205A1 (ru) * 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
AU2016274956A1 (en) 2015-06-11 2017-12-14 Usher Iii Initiative, Inc. Methods of treating or preventing a proteopathy

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002507996A (ja) 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
WO2000001697A1 (en) 1998-07-02 2000-01-13 Du Pont Pharmaceuticals Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
JP2008540664A (ja) 2005-05-16 2008-11-20 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としてのピロロピリジン誘導体
JP2009523812A (ja) 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
JP2010508363A (ja) 2006-11-01 2010-03-18 バーテックス ファーマシューティカルズ インコーポレイテッド ヤヌスキナーゼの阻害剤として有用な三環系ヘテロアリール化合物
JP2010528026A (ja) 2007-05-18 2010-08-19 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのキノリン誘導体
JP2010537998A (ja) 2007-08-27 2010-12-09 ワイス・エルエルシー イミダゾピリジン類似体、およびＷｎｔ−βカテニン細胞メッセージ伝達系のアゴニストとしてのその使用
JP2013529196A (ja) 2010-05-14 2013-07-18 メディカル リサーチ カウンシル テクノロジー キナーゼｌｒｒｋ２の阻害剤としてのピラゾロピリジン
JP2017502940A (ja) 2013-12-11 2017-01-26 セルジーン クオンティセル リサーチ，インク． リジン特異的デメチラーゼ−１の阻害剤
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
JP2020506197A (ja) 2017-02-07 2020-02-27 デウン ファーマシューティカル カンパニー リミテッド 新規なヘテロ環化合物、その製造方法およびこれを含む薬学的組成物

Also Published As

Publication number Publication date
AU2018269947A1 (en) 2019-12-19
CN110914265A (zh) 2020-03-24
AU2022200197A1 (en) 2022-02-10
WO2018213211A1 (en) 2018-11-22
US11168082B2 (en) 2021-11-09
AU2018269947B2 (en) 2021-10-14
JP2020519667A (ja) 2020-07-02
EP3628044A1 (en) 2020-04-01
US20200157091A1 (en) 2020-05-21
EP3628044B1 (en) 2023-11-22
CN110914265B (zh) 2022-12-23

Similar Documents

Publication Publication Date Title
CN110914265B (zh) 作为lsd-1抑制剂的吡咯并[2,3-c]吡啶和相关类似物
US11045448B2 (en) Piperidines as covalent menin inhibitors
JP2022548775A (ja) スピロ環式アンドロゲン受容体タンパク質分解剤
US20240150360A1 (en) Small Molecule Degraders of CBP/p300 Proteins
AU2017246452A1 (en) MDM2 protein degraders
JP2019514950A (ja) メニン阻害剤としてのピペリジン
CN112119080B (zh) 作为lsd-1抑制剂的咪唑并[4,5-c]吡啶化合物
KR20200136958A (ko) 공유 메닌 억제제로서의 피페리딘 화합물
AU2019280356A1 (en) ERK inhibitor and use thereof
WO2022187419A1 (en) Small molecule degraders of androgen receptor
WO2021207310A1 (en) Menin inhibitors and methods of use for treating cancer
WO2021067215A1 (en) Piperidine compounds as menin inhibitors
WO2023056589A1 (en) Menin inhibitors and methods of use for treating cancer
HK40022861A (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
HK40022861B (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
HK40041770A (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40041770B (en) Imidazo[4,5-c]pyridine compounds as lsd-1 inhibitors
HK40026020B (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors
HK40026020A (en) Pyrrolo[2,3-c]pyridines and related analogs as lsd-1 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210513

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230303

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230621

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230908

R150 Certificate of patent or registration of utility model

Ref document number: 7352284

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150